What Our Analysts Know About DaVita

By Susan Ramirez • Friday, October 28 12:00 • Permanent Link

Mid-cap Healthcare company DaVita has moved -26.3% so far today on a volume of 4,455,263, compared to its average of 684,306. In contrast, the S&P 500 index moved 2.3%

DaVita trades -29.01% away from its average analyst target price of $100.38 per share. The 8 analysts following the stock have set target prices ranging from $90 to $117, and on average have given DaVita a rating of hold.

Below are some factors that could be affecting the stocks's performance and analyst recommendation:

DaVita has moved -6.3% over the last year, and the S&P 500 logged a change of -17.3%
Based on its trailing earning per share of 7.87, DaVita has a trailing 12 month Price to Earnings (P/E) ratio of 9.1 while the S&P 500 average is 15.97
DVA has a forward P/E ratio is 7.2 based on its forward 12 month price to earnings (Eps) is $7.87 per share
The company has a price to earnings growth (PEG) ratio of 1.75 -- a number near or below 1 signifying that DaVita is fairly valued compared to its estimated growth potential
Its Price to Book (P/B) ratio is 10.9 compared to its sector average of 4.07

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure. Based in Denver, the company has 69,000 full time employees and a market cap of $6,506,038,272.

If you would like more in-depth discussions of stocks such as DaVita, subscribe to our free newsletter!

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.